Status:

COMPLETED

Desidustat in the Management of COVID-19 Patients

Lead Sponsor:

Zydus Lifesciences Limited

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COV...

Detailed Description

This is a phase 2b, multicenter, open-label, randomized, comparator-controlled clinical trial to evaluate the efficacy and safety of Desidustat for the management of COVID-19 patients. First 12 mild t...

Eligibility Criteria

Inclusion

  • Ability to comprehend and willingness to sign a written ICF by the subject/impartial witness.
  • Male and Females, age ≥18 years at enrollment.
  • Understands and agrees to comply with planned study procedures.
  • Agrees to the collection of pharyngeal swabs and blood sample as per protocol.
  • Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen within one week.
  • Illness of any duration, and at least one of the following:
  • Radiographic infiltrates by imaging (chest x-ray)
  • Clinical assessment (evidence of rales/crackles or other clinical symptoms on exam).
  • Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study (acceptable methods will be determined by the site).

Exclusion

  • ALT/AST \>5 times the upper limit of normal.
  • Stage V CKD (i.e. eGFR \<15 ml/min/1.73 m2 or requiring dialysis).
  • Pregnant or breast feeding.
  • Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment.
  • Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.
  • Prolong QT interval (\>450 ms).
  • Patients on invasive mechanical ventilation.

Key Trial Info

Start Date :

July 25 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 31 2021

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04463602

Start Date

July 25 2020

End Date

March 31 2021

Last Update

April 23 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Avant Sante Site 1

Monterrey, Mexico